Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-18 5:21 pm Unchanged | 2025-02-18 | 13D | Arbutus Biopharma Corporation ABUS | Roivant Sciences Ltd. ROIV | 38,847,462 20.500% | 0 (Unchanged) | Filing History |
| 2025-02-14 2:00 pm Sale | 2024-12-31 | 13G | Roivant Sciences Ltd. ROIV | QVT Financial LP | 65,793,779 9.220% | -926,000 (-1.39%) | Filing History |
| 2025-02-14 09:59 am Sale | 2024-12-31 | 13G | Roivant Sciences Ltd. ROIV | SB Investment Advisers (UK) Limited | 62,057,537 8.500% | -10,974,130 (-15.03%) | Filing History |
| 2025-01-15 4:30 pm Purchase | 2025-01-13 | 13D | Immunovant, Inc. IMVT | Roivant Sciences Ltd. ROIV | 96,660,341 56.900% | 16,845,010 (+21.10%) | Filing History |
| 2024-11-14 4:31 pm Sale | 2024-09-30 | 13G | Roivant Sciences Ltd. ROIV | VIKING GLOBAL INVESTORS LP | 54,099,066 7.300% | -15,269,895 (-22.01%) | Filing History |
| 2024-11-12 4:58 pm Unchanged | 2024-09-30 | 13G | Roivant Sciences Ltd. ROIV | VANGUARD GROUP INC | 41,683,055 5.630% | 0 (Unchanged) | Filing History |
| 2024-11-12 10:34 am Purchase | 2024-11-08 | 13G | Roivant Sciences Ltd. ROIV | FMR LLC | 49,145,056 6.645% | 49,145,056 (New Position) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Roivant Sciences Ltd. ROIV | BlackRock Inc. BLK | 41,962,059 5.700% | 0 (Unchanged) | Filing |
| 2024-11-04 10:47 am Purchase | 2024-09-30 | 13G | Roivant Sciences Ltd. ROIV | VANGUARD GROUP INC | 41,683,055 5.630% | 41,683,055 (New Position) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Roivant Sciences Ltd. ROIV | BlackRock Inc. BLK | 41,962,059 5.700% | 41,962,059 (New Position) | Filing |
| 2024-04-02 4:06 pm Sale | 2024-04-02 | 13G | Roivant Sciences Ltd. ROIV | Sumitomo Chemical Co. Ltd. | 0 0.000% | -71,251,083 (Position Closed) | Filing History |
| 2024-03-07 5:33 pm Sale | 2024-03-07 | 13G | Roivant Sciences Ltd. ROIV | QVT Financial LP | 66,719,779 8.280% | -45,821,757 (-40.72%) | Filing History |
| 2024-02-14 4:46 pm Unchanged | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | Ramaswamy Vivek | 81,454,521 9.750% | 0 (Unchanged) | Filing History |
| 2024-02-14 11:14 am Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | QVT Financial LP | 112,541,536 13.970% | -10,000,000 (-8.16%) | Filing History |
| 2024-02-14 10:20 am Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | VIKING GLOBAL INVESTORS LP | 69,368,961 8.600% | -5,869,739 (-7.80%) | Filing History |
| 2024-02-14 06:51 am Unchanged | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | Dexcel Pharma Technologies Ltd. | 102,849,443 12.780% | 0 (Unchanged) | Filing History |
| 2024-02-13 5:26 pm Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | Ramaswamy Vivek | 81,454,521 9.750% | -328,720 (-0.40%) | Filing History |
| 2024-02-13 5:00 pm Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | SB Investment Advisers (UK) Limited | 73,031,667 9.100% | -22,000,000 (-23.15%) | Filing History |
| 2024-02-01 5:24 pm Sale | 2023-12-31 | 13G | Roivant Sciences Ltd. ROIV | Sumitomo Chemical Co. Ltd. | 71,251,083 8.860% | -15,116,277 (-17.50%) | Filing History |
| 2023-10-04 5:19 pm Purchase | 2023-10-02 | 13D | Immunovant, Inc. IMVT | Roivant Sciences Ltd. ROIV | 79,815,331 55.300% | 6,416,667 (+8.74%) | Filing History |